| Bioactivity | BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1]. | ||||||||||||
| Invitro | BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries[1]. | ||||||||||||
| In Vivo | BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow[1]. Animal Model: | ||||||||||||
| Name | BGC-20-1531 free base | ||||||||||||
| CAS | 736183-35-0 | ||||||||||||
| Formula | C26H24N2O6S | ||||||||||||
| Molar Mass | 492.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Maubach KA, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327. |
BGC-20-1531 free base
CAS: 736183-35-0 F: C26H24N2O6S W: 492.54
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.